

Philip Livingston and Friedhelm Hellung
U.S. Serial No.: 08/477,097
Filed: June 7, 1995
Page 2

On page 5, line 15, please delete "(a)" and insert --(Figure 3A) --

--

✓

On page 5, line 15, please delete "(b)" and insert --(Figure 3B) --

--

✓

On page 5, line 30, please delete "(a)" and insert --(Figure 6A) --

--

✓

On page 5, line 31, please delete "(b)" and insert --(Figure 6B) --

--

✓

On page 7, line 17, after "IgM", please insert --(Figure 10A) --.

On page 7, line 17, after "IgG", please insert --(Figure 10B) --.

NE On page 114, line 16, please wrap "(by logrank test). A similar trend was seen for survival (p = .08 by logrank test)." after ".02."

In the claims:

Please cancel claim 5 without prejudice.

In accordance with 37 C.F.R. §1.121(b), please amend claims 1, 8 and 13 by adding the underlined material and deleting the bracketed material as follows:

1
--1. (Amended) A vaccine for stimulating or enhancing in a subject to which the vaccine is administered, production of an antibody which recognizes a ganglioside, comprising an amount of ganglioside, which is selected from the group consisting of GM2, GM3, GD2, GD3, GD3 lactone, O-Acetyl GD3 and GT3, or oligosaccharide portion thereof, conjugated to an immunogenic protein effective to stimulate or enhance antibody production in the subject, an effective amount of adjuvant and a pharmaceutically acceptable vehicle.--

2
--8. (Amended) The vaccine of claim [5] 1, wherein the effective